Why did Divi's Laboratories (DIVISLAB) stock move recently?

On 8/4/2026, Divi's Laboratories moved +4.0% — Divi's Labs shares rose on a strong Q1 FY27 beat, with net profit surging 66% YoY to ₹902 crore and revenue up 28% to ₹3,080 crore, beating estimates, alongside management reaffirming double-digit revenue growth guidance for FY27. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Divi's Laboratories (DIVISLAB) overvalued or fairly valued?

MarketChacha shows Divi's Laboratories's valuation in context — a forward P/E of about 60.1, a price-to-book of about 14.4 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Divi's Laboratories's revenue?

Divi's Laboratories reported revenue of ₹10,388 Cr for FY2026, with net profit of ₹2,607 Cr, per official filings.

What is the share price of Divi's Laboratories (DIVISLAB)?

Divi's Laboratories last traded at ₹9,087.00 (-0.6% on the day), as of 10/19/2026 — a delayed quote shown for education, not investment advice.

Divi's Laboratories

DIVISLAB · NSE · Pharma · India

Snapshot

TickerDIVISLAB

ExchangeNSE

SectorPharma

IndustryDrug Manufacturers - Specialty & Generic

CountryIndia

Employees11,565

HeadquartersHyderabad, India

Websitewww.divislabs.com

Filings tracked0

About Divi's Laboratories

Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as astaxanthin, beta-carotene, lycopene, canthaxanthin, apocarotenal, and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.

Who owns it

Promoters52.0%
Institutions29.2%
Public & other18.8%

235 institutional holders

Ownership breakdown from public market data. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend23.5% → 24.3%

Margin has held broadly steady over the period — stable profitability.

Growth qualityrev 8% · PAT 9%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹2,948 Cr · EPS 26.63

Est. earnings growth +10.6%

Next fiscal year

Rev ₹15,030 Cr · EPS 151.24

Est. earnings growth +22.4%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 5

Revenue (FY2026)

₹10,560 Cr

Net margin

24.3%

Revenue CAGR (3y)

+10.8%

Profit CAGR (3y)

+12.1%

Net profit (FY2026)

₹2,568 Cr

Ask MarketChacha about DIVISLAB

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Aug 4, 2026
Divi's Labs shares rose on a strong Q1 FY27 beat, with net profit surging 66% YoY to ₹902 crore and revenue up 28% to ₹3,080 crore, beating estimates, alongside management reaffirming double-digit revenue growth guidance for FY27.
source 1 ↗source 2 ↗source 3 ↗· confidence: high
Jul 29, 2026
Divi's Laboratories shares rose with the broader Indian market and likely the pharma sector, which advanced on positive sentiment with no company-specific catalyst identified.
· confidence: low

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹10,560 Cr	₹2,568 Cr	24.3%
FY2025	₹9,360 Cr	₹2,191 Cr	23.4%
FY2024	₹7,845 Cr	₹1,600 Cr	20.4%
FY2023	₹7,768 Cr	₹1,823 Cr	23.5%

Quarterly

Period	Revenue	Net profit	Net margin
Q1 FY27	₹3,080 Cr	₹902 Cr	29.3%
Q4 FY26	₹2,831 Cr	₹751 Cr	26.5%
Q3 FY26	₹2,604 Cr	₹583 Cr	22.4%
Q2 FY26	₹2,715 Cr	₹689 Cr	25.4%
Q1 FY26	₹2,410 Cr	₹545 Cr	22.6%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.